A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase

Nature Medicine

Volumn 5, Issue 3, 1999, Pages 280-285

  Craft, Noah ^a   Shostak, Yukiy ^b   Carey, Michael ^a,b   Sawyers, Charles L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; ONCOPROTEIN; PROSTATE SPECIFIC ANTIGEN; PROTEIN TYROSINE KINASE;

ARTICLE; CANCER GROWTH; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; HORMONE RESISTANCE; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT;

ANDROGENS; ANIMALS; HUMANS; MALE; MICE; MICE, SCID; NEOPLASM TRANSPLANTATION; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECEPTOR, ERBB-2; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION; TRANS-ACTIVATION (GENETICS); TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

ANIMALIA;

EID: 0033022342     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/6495     Document Type: Article

References (45)

1. Talpin, M.E. et al. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N. Engl. J. Med. 332, 1393-1398 (1995).
2. Gaddipati, J.P. et al. Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers. Cancer Res. 54, 2861-2864 (1994).
3. Visakorpi, T. et al. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nature Genet. 9, 401-406 (1995).
4. Veldscholte, J. et al. The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens. J. Steroid Biochem. Mol. Biol. 41, 665-669 (1992).
5. Ignar-Trowbridge, D.M. et al. Coupling of dual signaling pathways: epidermal growth factor action involves the estrogen receptor. Proc. Natl. Acad. Sci. USA 89, 4658-4662 (1992).
6. Power, R.F., Mani, S.K., Codina, J., Conneely, O.M. & O'Malley, B.W. Dopaminergic and ligand-independent activation of steroid hormone receptors. Science 254, 1636-1639 (1991).
7. Aronica, S.M. & Katzenellenbogen, B.S. Stimulation of estrogen receptor-mediated transcription and alteration in the phosphorylation state of the rat uterine estrogen receptor by estrogen, cyclic adenosine monophosphate, and insulin-like growth factor-1. Mol. Endocrinol. 7, 743-752 (1993).
8. Denner, L.A., Weigel, N.L., Maxwell, B.L., Schrader, W.T., & O'Malley, B.W. Regulation of progesterone receptor-mediated transcription by phosphorylation. Science 250, 1740-1743 (1990).
9. Kato, S. et al. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 270, 1491-1494 (1995).
10. Culig, Z. et al. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-1, keratinocyte growth factor, and epiderman growth factor. Cancer Res. 54, 5474-5478 (1994).
11. Slamon, D.J. et al. Studies of the Her-2/neu proto-oncogene in human breast and ovarian cancer. Science 244, 707-712 (1989).
12. Adnane, J. et al. Proto-oncogene amplification and human breast tumor phenotype. Oncogene 4, 1389-1395 (1989).
13. Zeillinger, R. et al. HER-2 amplification, steroid receptors and epidermal growth factor receptor in primary breast cancer. Oncogene 4, 109-114 (1989).
14. Borg, A. et al. ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer. Cancer Lett. 81, 137-144 (1994).
15. Leitzel, K. et al. Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer. J. Clin. Oncol. 13, 1129-1135 (1995).
16. Pietras, R.J. et al. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 10, 2435-2446 (1995).
17. Ware, J.L., Maygarden, S.J., Koontz, W.W. Jr. & Strom, S.C. Immunohistochemical detection of c-erbB-2 protein in human benign and neoplastic prostate. Hum. Pathol. 22, 254-258 (1991).
18. Robinson, D., He, F., Preglow, T. & Kung, H.J. A tyrosine kinase profile of prostate carcinoma. Proc. Natl. Acad. Sci. USA 93, 5958-5962 (1996).
19. Lyne, J.C. et al. Tissue expression of neu differentiation factor/heregulin and its receptor complex in prostate cancer and its biological effects on prostate cancer cells in vitro. Cancer J. Sci. Am. 3, 21-30 (1997).
20. Mellon, K. et al. p53, c-erbB-2 and the epidermal growth factor receptor in the benign and malignant prostate. J. Urol. 147, 496-499 (1992).
21. Kuhn, E.J., Kurnot, R.A., Sesterhenn, I.A., Chang, E.H. & Moul, J.W. Expression of the c-erb-B-2 (HER-2/neu) oncoprotein in human prostatic carcinoma. J. Urol. 150, 1427-1433 (1993).
22. Sadasivan, R. et al. Overexpression of HER-2/Neu may be an indicator of poor prognosis in prostate cancer. J. Urol. 150, 126-131 (1993).
23. Ross, J.S. et al. Prognostic significance of HER-2/neu gene amplification status by fluorescence in situ hybridization of prostate carcinoma. Cancer 79, 2162-2170 (1997).
24. Arai, Y., Tatsuhiro, T. & Yoshida, O. C-erbB-2 oncoprotein: a potential biomarker of advanced prostate cancer. Prostate 30, 195-201 (1997).
25. Klein, K.A. et al. Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice. Nature Med. 3, 402-408 (1997).
26. Romijn, J.C., Verkoelen, C.F. & Schroeder, F.H. Application of the MTT assay to human prostate cancer cell lines in vitro: establishment of test conditions and assessment of hormone-stimulated growth and drug-induced cytostatic and cytotoxic effects. Prostate 12, 99-110 (1988).
27. Nagabhushan, M. et al. CWR22: the first human prostate cancer xenograft with strongly androgen-dependent and relapsed strains both in vivo and in soft agar. Cancer Res. 56, 3042-3046 (1996).
28. Kyprianou, N., English, HF. & Isaacs, JT. Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation. Cancer Res. 50, 3748-3753 (1990).
29. Woll, D.A., Schulz, P. & Fittler, F. Transcriptional regulation of prostate kallikrein-like genes by androgen. Mol. Endocrinol. 6, 753-762 (1992).
30. Cleutjens, K.B.J.M. et al. An androgen response element in a far upstream enhancer region is essential for high, androgen-regulated activity of the prostate-specific antigen promoter. Mol. Endocrinol. 11, 148-161 (1997).
31. Schurr, E.R. et al. Prostate-specific antigen expression is regulated by an upstream enhancer. J. Biol. Chem. 271, 7043-7051 (1996).
32. Pang, S. et al. Identification of a positive regulatory element responsible for tissue-specific expression of prostate-specific antigen. Cancer Res. 57, 495-499 (1997).
33. Wang, E.H., Zou, S. & Tjian, R. TAFII250-dependent transcription of cyclin A is directed by ATF activator proteins. Genes Dev. 11, 2658-2669 (1997).
34. Riegman, P.H.J., Vlietstra, R.J., van der Korput, J.A.G.M., Brinkmann, A.O. & Trapman, J. The promoter of the prostate-specific antigen gene contains a functional androgen responsive element. Mol. Endocrinol. 5, 1921-1930 (1991).
35. Chan, J.M. et al. Plasma insulin-like growth factor-1 and prostate cancer risk: a prospective study. Science 279, 563-566 (1998).
36. Burfeind, P., Chernicky, C.L., Rininsland, F. & Ilan, J. Antisense RNA to the type 1 insulin-like growth factor receptor suppresses tumor growth and prevents invasion by rat prostate cancer cell in vivo. Proc. Natl. Acad. Sci. USA 93, 7263-7268 (1996).
37. Ben-Levy, R., Paterson, H.F., Marshall, C.J. & Yarden, Y. A single autophosphorylation site confers oncogenicity to the Neu/ErbB-2 receptor and enables coupling to the MAP kinase pathway. EMBO J. 13, 3302-3311 (1994).
38. Bunone, C., Briand, P.-A., Miksicek, R.J. & Picard, D. Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. EMBO J. 15, 2174-2183 (1996).
39. Janknecht, R. & Hunter, T. A growing coactivator network. Nature 383, 22-23 (1996).
40. Glass, C.K., Rose, D.W. & Rosenfeld, M.G. Nuclear receptor coactivators. Curr. Opin. Cell. Biol. 9, 222-232 (1997).
41. +a (humanized anti-HER2 antibody) as a single agent in 222 women with HER2 overexpression who relapsed following chemotherapy for metastatic breast cancer. Progr/Proc. Am. Soc. Clin. Oncol. 17, 97a (1998).
42. Slamon, D. et al. Addition of Herceptin (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer (HER2+/MBC) markedly increases anticancer activity: a randomized, multinational controlled phase III trial. Progr/Proc. Am. Soc. Clin. Oncol. 17, 98a (1998).
43. Chazin, V.R., Kaleko, M., Miller, A.D. & Slamon, D.J. Transformation mediated by the human HER-2 gene independent of the epidermal growth factor receptor. Oncogene, 7, 1859-1866 (1992).
44. Emami, K.H. & Carey, M.A synergistic increase in potency of a multimerized VP16 transcriptional activation domain. EMBO J. 11, 5005-5012 (1992).
45. Raitano, A.B., Halpern, J.R., Hambuch, T.M. & Sawyers, C.L. The Bcr-Abl leukemia oncogene activates Jun Kinase and requires Jun for transformation. Proc. Natl Acad. Sci. USA 92, 11746-50 (1995).